Menu
Innovation Observatory > Reports > Drugs > Larotrectinib (LOXO-101) for advanced solid cancers [with an NTRK1, NTRK2, or NTRK3 gene fusion]

< Back

Larotrectinib (LOXO-101) for advanced solid cancers [with an NTRK1, NTRK2, or NTRK3 gene fusion]

Drugs

Cancer and Palliative Care

June 2017


Due to new technologies, rearrangement of genes in cells can be discovered which result in two normally separate genes being brought together (a fusion), which can cause abnormalities in control of cell growth leading to development of solid tumor cancers. Fusions of a family of normal genes called NTRK have been found to cause normal cells to become cancerous and can happen in cells of both adults and children. Many different solid tumor cancers have NTRK fusions. Blocking the activity of these fusions with an oral drug called larotrectinib can be a new method of cancer treatment. 

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts